HAEMONETICS CORP — Director's Dealing 2013

Jul 26, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-07-24

Reporting Person: HANLON SUSAN M (VP Finance)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-07-24	Performance Shares	$0.0	A	12500.0	Acquired	2017-12-31	Common Stock (12500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	16751	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$25.535	2014-10-24	Common Stock (7138)	7138	Direct
Non-Qualified Stock Option (right to buy)	$26.47	2016-10-27	Common Stock (14690)	14690	Direct
Non-Qualified Stock Option (right to buy)	$27.275	2015-10-22	Common Stock (7206)	7206	Direct
Non-Qualified Stock Option (right to buy)	$27.495	2017-10-27	Common Stock (22348)	22348	Direct
Non-Qualified Stock Option (right to buy)	$30.67	2018-10-25	Common Stock (20726)	20726	Direct
Non-Qualified Stock Option (right to buy)	$39.055	2019-10-24	Common Stock (16882)	16882	Direct

Footnotes

F1: Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).

F2: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.